FluoSphera
Private Company
Total funding raised: $2.8M
Overview
FluoSphera has developed a novel, chip-free platform for high-throughput drug discovery that utilizes compartmentalized, color-coded 3D human organ-like microtissues. This system is designed to model the systemic interactions between organs mediated by blood-soluble factors, providing a more physiologically relevant model for predicting drug efficacy, toxicity, and mechanism of action before clinical trials. The company offers integrated discovery products (FluoSelect, FluoScore, FluoXplore) and has established a partnership with Revvity, indicating a platform-as-a-service business model targeting pharmaceutical and biotech clients. Headquartered in Lausanne, Switzerland, with a US presence in Boston, FluoSphera is a private, likely pre-revenue company positioned to address a critical bottleneck in translational research.
Technology Platform
A chip-free platform using color-coded, encapsulated 3D human organ-like microtissues that communicate via soluble factors to mimic systemic physiology for predictive drug discovery and profiling.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
FluoSphera competes in the advanced preclinical models space, which includes organ-on-a-chip companies (e.g., Emulate, Mimetas), 3D cell culture specialists, and service providers offering complex assay systems. Its key differentiators are its unique color-coded capsule system for easy tissue multiplexing without labels, its chip-free design aimed at high-throughput compatibility, and its integrated offering from screening to omics analysis.